Display options
Cite
Burke L, Butler CT, Murphy A, et al. Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Front Cell Dev Biol. 2016;4:103doi: 10.3389/fcell.2016.00103.
Burke, L., Butler, C. T., Murphy, A., Moran, B., Gallagher, W. M., O'Sullivan, J., & Kennedy, B. N. (2016). Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Frontiers in cell and developmental biology, 4103. https://doi.org/10.3389/fcell.2016.00103
Burke, Lorraine, et al. "Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer." Frontiers in cell and developmental biology vol. 4 (2016): 103. doi: https://doi.org/10.3389/fcell.2016.00103
Burke L, Butler CT, Murphy A, Moran B, Gallagher WM, O'Sullivan J, Kennedy BN. Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer. Front Cell Dev Biol. 2016 Sep 21;4:103. doi: 10.3389/fcell.2016.00103. eCollection 2016. PMID: 27709113; PMCID: PMC5030284.
Copy Download .nbib Format: NLM
Share it on

Front Cell Dev Biol. 2016 Sep 21;4:103. doi: 10.3389/fcell.2016.00103. eCollection 2016.

Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer.

Frontiers in cell and developmental biology

Lorraine Burke, Clare T Butler, Adrian Murphy, Bruce Moran, William M Gallagher, Jacintha O'Sullivan, Breandán N Kennedy

Affiliations

  1. UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College DublinDublin, Ireland; Translational Oncology, Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, St. James's HospitalDublin, Ireland.
  2. UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin Dublin, Ireland.
  3. Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital Baltimore, MD, USA.
  4. Trinity Translational Medicine Institute, Department of Surgery, Trinity College Dublin, St. James's Hospital Dublin, Ireland.

PMID: 27709113 PMCID: PMC5030284 DOI: 10.3389/fcell.2016.00103

Abstract

Colorectal cancer is the third most common cancer worldwide and is associated with significant morbidity and mortality. Current pharmacotherapy options include cytotoxic chemotherapy, anti-VEGF, and anti-EGFR targeting drugs, but these are limited by toxic side effects, limited responses and ultimately resistance. Cysteinyl leukotriene (CysLT) signaling regulates intestinal homeostasis with mounting evidence suggesting that CysLT signaling also plays a role in the pathogenesis of colorectal cancer. Therefore, CysLT signaling represents a novel target for this malignancy. This review evaluates reported links between CysLT signaling and established hallmarks of cancer in addition to its pharmacological potential as a new therapeutic target.

Keywords: colorectal cancer; cysteinyl leukotriene; cysteinyl leukotriene receptor antagonist; eicosanoid; hallmarks of cancer; tumorigenesis

References

  1. Inflamm Bowel Dis. 2007 May;13(5):537-46 - PubMed
  2. J Cell Sci. 2002 May 1;115(Pt 9):1883-93 - PubMed
  3. PLoS One. 2013 Sep 05;8(9):e73466 - PubMed
  4. BMC Cancer. 2013 Jul 08;13:336 - PubMed
  5. J Pharmacol Sci. 2009 Feb;109(2):285-92 - PubMed
  6. Eur J Pharmacol. 1994 Jun 2;258(1-2):151-4 - PubMed
  7. Clin Cancer Res. 2009 Apr 15;15(8):2583-7 - PubMed
  8. J Biol Chem. 2005 Apr 8;280(14):13538-44 - PubMed
  9. J Biol Chem. 2003 Nov 14;278(46):45577-85 - PubMed
  10. Science. 1998 Sep 4;281(5382):1509-12 - PubMed
  11. Pharmazie. 2010 Oct;65(10):750-4 - PubMed
  12. Cancer Sci. 2014 Mar;105(3):290-6 - PubMed
  13. Eur J Cancer. 2010 Mar;46(4):826-35 - PubMed
  14. Ann Intern Med. 1994 Nov 1;121(9):684-97 - PubMed
  15. Nature. 2004 May 13;429(6988):188-93 - PubMed
  16. Eur J Cancer. 2012 Jul;48(10):1466-75 - PubMed
  17. Thromb Haemost. 1996 Jul;76(1):99-104 - PubMed
  18. Am J Pathol. 1998 Aug;153(2):333-9 - PubMed
  19. Am J Transl Res. 2010 Jan 01;2(1):65-74 - PubMed
  20. J Immunol. 2004 Aug 1;173(3):1503-10 - PubMed
  21. Clin Cancer Res. 2008 Oct 15;14(20):6525-30 - PubMed
  22. J Mol Cell Biol. 2011 Feb;3(1):1-3 - PubMed
  23. Biochem Soc Trans. 2005 Aug;33(Pt 4):698-700 - PubMed
  24. Oncogene. 2006 Oct 26;25(50):6660-5 - PubMed
  25. Clin Exp Allergy. 2006 Jun;36(6):689-703 - PubMed
  26. Proc Natl Acad Sci U S A. 2016 May 31;113(22):6242-7 - PubMed
  27. Oncol Rep. 2007 Jul;18(1):99-104 - PubMed
  28. N Engl J Med. 1971 Nov 18;285(21):1182-6 - PubMed
  29. Glia. 2013 Jul;61(7):1155-71 - PubMed
  30. J Biol Chem. 2006 Mar 10;281(10 ):6776-84 - PubMed
  31. Nature. 1999 Jun 24;399(6738):789-93 - PubMed
  32. Gastroenterology. 2000 Oct;119(4):1007-18 - PubMed
  33. EMBO J. 2006 Oct 4;25(19):4615-27 - PubMed
  34. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  35. Cell. 1991 Jun 14;65(6):1043-51 - PubMed
  36. J Pathol. 2005 Jan;205(2):275-92 - PubMed
  37. PLoS One. 2011;6(12 ):e29060 - PubMed
  38. FASEB J. 2008 Oct;22(10):3525-36 - PubMed
  39. J Immunol. 2010 Aug 1;185(3):1846-54 - PubMed
  40. Am Rev Respir Dis. 1987 Feb;135(2):333-7 - PubMed
  41. Cancer Med. 2013 Oct;2(5):662-73 - PubMed
  42. Sci Rep. 2013 Nov 20;3:3274 - PubMed
  43. Surgery. 2001 Aug;130(2):363-9 - PubMed
  44. J Biol Chem. 1989 Aug 5;264(22):12885-9 - PubMed
  45. Mol Cell Biol. 2007 May;27(9):3282-9 - PubMed
  46. Nat Genet. 1998 Nov;20(3):291-3 - PubMed
  47. Cancer Res. 2007 Oct 1;67(19):9190-8 - PubMed
  48. Am J Pathol. 2008 Mar;172(3):592-602 - PubMed
  49. Am J Pathol. 2001 Jan;158(1):3-9 - PubMed
  50. Urology. 2009 Apr;73(4):916-21 - PubMed
  51. J Allergy Clin Immunol. 2003 Aug;112(2):369-74 - PubMed
  52. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  53. World J Gastroenterol. 2014 Jan 28;20(4):968-77 - PubMed
  54. Clin Cancer Res. 2012 Oct 15;18(20):5546-53 - PubMed
  55. Trends Pharmacol Sci. 1991 Feb;12 (2):68-70 - PubMed
  56. J Lipid Mediat. 1993 Mar-Apr;6(1-3):313-20 - PubMed
  57. Cell. 1996 Oct 18;87(2):159-70 - PubMed
  58. Nat Rev Drug Discov. 2004 May;3(5):391-400 - PubMed
  59. J Cell Mol Med. 2014 Sep;18(9):1785-96 - PubMed
  60. Mol Cancer Ther. 2006 Nov;5(11):2716-26 - PubMed
  61. J Biol Chem. 2013 Apr 19;288(16):10967-72 - PubMed
  62. Cancer Res. 2004 Jun 1;64(11):3892-9 - PubMed
  63. Cardiovasc Res. 2007 Oct 1;76(1):160-6 - PubMed
  64. J Allergy Clin Immunol. 2004 Nov;114(5):1093-9 - PubMed
  65. Gastroenterology. 2010 Jun;138(6):2044-58 - PubMed
  66. Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):e37-41 - PubMed
  67. J Biol Chem. 2016 Apr 1;291(14):7242-55 - PubMed
  68. Int Arch Allergy Immunol. 2009;149(3):275-82 - PubMed
  69. Ann Surg. 2010 Feb;251(2):254-60 - PubMed
  70. PLoS One. 2015 Mar 06;10 (3):e0121402 - PubMed
  71. Biochem Biophys Res Commun. 2003 Mar 7;302(2):330-5 - PubMed
  72. Nat Rev Cancer. 2003 Jun;3(6):401-10 - PubMed
  73. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):321-30 - PubMed
  74. Int J Cancer. 2011 Jul 1;129(1):9-22 - PubMed
  75. J Biol Chem. 2008 Jan 25;283(4):1974-84 - PubMed
  76. Gastroenterology. 2010 Jun;138(6):2073-2087.e3 - PubMed
  77. Cancer. 2001 Feb 15;91(4):854-62 - PubMed
  78. Sci Signal. 2013 Oct 22;6(298):ra93 - PubMed
  79. Chest. 2004 May;125(5):1700-5 - PubMed
  80. Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11685-90 - PubMed
  81. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  82. J Biol Chem. 2001 Jun 1;276(22):18934-40 - PubMed
  83. J Clin Oncol. 2007 Oct 20;25(30):4779-86 - PubMed
  84. Drugs. 2008;68(4):487-506 - PubMed
  85. Prostaglandins Leukot Essent Fatty Acids. 2008 Dec;79(6):223-31 - PubMed
  86. Clin Exp Allergy. 2011 Feb;41(2):204-17 - PubMed
  87. Brain. 2009 Aug;132(Pt 8):2206-18 - PubMed
  88. Clin Exp Immunol. 2009 Oct;158(1):1-9 - PubMed
  89. Blood. 2007 Nov 1;110(9):3263-70 - PubMed
  90. Br J Cancer. 2009 Nov 3;101(9):1596-605 - PubMed
  91. Clin Exp Allergy. 2012 Sep;42(9):1313-20 - PubMed
  92. Exp Cell Res. 2014 Feb 15;321(2):255-66 - PubMed
  93. Nat Commun. 2015 Dec 11;6:10112 - PubMed
  94. J Gastroenterol. 1995 Feb;30(1):34-40 - PubMed

Publication Types